Patients with RRMM with renal impairment demonstrated similar efficacy and safety outcomes with talquetamab as those without renal impairment.

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL. Combination odronextamab plus CHOP had promising response rates with a ...

Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.

Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...